Ajay Kumar / Ph.D., Molecular Biology & Microbiology / Boston, MA
Translational
drug discovery,
end‑to‑end.
Principal Scientist with 15+ years driving discovery–to–IND programs in immunology and rare disease. Hands-on at the bench. Leading translational biomarker and pharmacology strategy.
Ajay Kumar, Ph.D.
Principal Scientist // Translational Lead
42.3601°N // 71.0589°W
[ Career: 2003 → present ] Affiliations
[ tenure ]
15+yr
Driving discovery-to-IND programs across industry and academic translational labs.
[ publications ]
12
Peer-reviewed including Hum. Mol. Genet., PLoS One, J. Med. Chem., J. Vis. Exp.
[ ip ]
2pat
Co-inventor on patents filed across US, EU, AU, CA, and via WIPO.
[ presentations ]
30+
Posters and talks at MDA, WMS, Cure Duchenne, and other muscle-focused forums.
01 / Positioning
A hands-on scientist who runs programs end-to-end.
My career has been built at the bench and in front of the matrix team. As a Principal Scientist I lead discovery programs from target identification through IND-enablement: designing the pharmacology cascade, executing the in vivo studies, building the translational biomarker package, and authoring the regulatory filings.
Domains: immunology & inflammation and rare disease. Modalities: small molecules through to AAV gene therapy and oligonucleotides. Across Entrada Therapeutics, Pfizer, and Boston University, I've shaped Target Product Profiles, qualified fit-for-purpose biomarker assays, managed CRO portfolios, and supported IND/CTA submissions.
I work where the science is hard and the clock is loud. I bring the rigor of a peer-reviewed publisher, the urgency of a startup operator, and a working fluency in AI/ML tools that are reshaping how preclinical biology gets done.
02 / Live / AI
Ask my AI
anything.
An assistant grounded in my full résumé, publication list, and patents. Recruiters and scientific hiring managers: ask away. Faster than reading the PDF.
Try: "What's his biomarker experience?" · "Tell me about the IGF-1 work." · "Has he led IND submissions?"
ak-assistant · gemini-flash
live
▌ AK · Assistant
Hi. I'm grounded entirely in Ajay's résumé, publications, and patents. I'll only answer questions about his professional background. Try one of the prompts below, or ask about his biomarker work, IND filings, AAV experience, or specific publications.
03 / Experience
From bench to boardroom.
Four chapters (academia, big pharma, focused biotech, a translational lab); each one sharpening the same instinct: read the data, read the room, place the right bet.
03 / 2021 — 05 / 2025
Entrada Therapeutics
Boston, MA
Principal Scientist // Translational Development & Biomarker Lead
Early-stage development & proof-of-mechanism strategy
- Led discovery programs from target identification to IND-enablement: defined scientific strategy and executed pharmacology cascades integrating cell signaling, PK/PD, and safety data to generate decision-quality data for inflammatory and fibrotic assets.
- Designed and executed in vivo PK/PD and efficacy studies in inflammatory and fibrotic disease models. Established pharmacodynamic endpoints, dose-response relationships, and proof-of-mechanism criteria supporting lead optimization and candidate selection for IND-enabling studies.
- Led the development, optimization, and validation of fit-for-purpose biomarker assays (multiplex ELISA, qPCR, high-content imaging, histopathology) in biofluids and tissues. Oversaw assay transfer and qualification for clinical implementation.
Translational strategy & regulatory
- Partnered cross-functionally to shape Target Product Profiles (TPPs) and clinical positioning. Authored IND submissions and biomarker strategies, integrating DMPK/safety learnings to drive stage-gate decisions and regulatory alignment for neuromuscular and rare-disease programs.
- Managed budget planning and cost modeling for complex study designs, validating assumptions to minimize variance and enable efficient study start-up in a resource-constrained environment.
Leadership & external partnership
- Led and developed a multidisciplinary team while remaining hands-on at the bench. Managed execution of high-content workflows and in vivo studies to meet aggressive startup timelines.
- Managed CRO partnerships for biology programs: vendor selection, SOW negotiations, study oversight ensuring data quality, regulatory compliance, and timely delivery.
- Communicated biology strategy, translational research plans, and program updates to internal stakeholders, executive leadership, board members, and external scientific advisors. Presented at scientific conferences and contributed to investor presentations.
EEV™ platform programs — DMD & DM1
- Endosomal Escape Vehicle (EEV™) platform: Proprietary cyclic cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PMOs) to overcome endosomal escape barriers for delivery into skeletal and cardiac muscle.
- EEV-PMO-23 (DMD, exon 23): Monthly/Q6W IV dosing in D2-mdx mice produced widespread exon 23 skipping and restored dystrophin across diaphragm and heart. Normalized serum creatine kinase (CK), significantly improved grip strength, wire hang time, and skeletal muscle contractile function to near wild-type levels.
- ENTR-601-44 (DMD, exon 44 skipping): Robust dose-dependent exon 44 skipping and dystrophin restoration in DMD patient-derived skeletal muscle cells. Single-dose NHP and hDMD mouse studies demonstrated durable exon skipping for at least 12 weeks in cardiac and skeletal muscle.
- ENTR-601-45 (DMD, exon 45 skipping): Q6W dosing in del44hDMD.mdx mice produced dose-dependent increases in dystrophin-positive fibers at the sarcolemma. Improved membrane stability and significant protection against eccentric-induced muscle damage. Efficacy confirmed in patient-derived myotubes and cardiomyocytes with exon 46-48 deletions.
- ENTR-601-50 / ENTR-601-51 (pipeline expansion): Robust exon skipping and dystrophin restoration in respective del51/del52 hDMD.mdx mouse models. ENTR-601-50 notably localized to satellite cells, potentially supporting muscle regeneration.
- ENTR-701 (DM1): Allele-specific EEV-PMO targeting toxic CUG repeats in DMPK mRNA to release MBNL1 and restore normal splicing. Reduced nuclear foci in HeLa480 and patient-derived cells (2,600 CUG repeats). Single IV dose in HSA-LR mice produced durable splicing correction of Mbnl1, Atp2a1, and Nfix; ameliorated pinch-induced myotonia for at least 8 weeks.
09 / 2016 — 03 / 2021
Pfizer, Inc.
Cambridge, MA
Senior Scientist // Gene Therapy & Early Development
CNS gene therapy & translational pharmacology
- Led translational biomarker strategies for AAV-based genetic medicine programs. Designed and executed studies to establish proof-of-mechanism and inform patient selection.
- Orchestrated development and deployment of novel molecular and functional assays (gene expression, protein quantitation) to monitor pharmacodynamics and efficacy, directly supporting dose selection for Phase I trials.
- Developed PK/PD frameworks for therapeutic programs. Designed tissue distribution, target engagement, and mechanistic efficacy studies supporting dose selection and clinical trial design. Established translational proof-of-concept criteria.
- Pioneered translational biomarker platforms evaluating mechanistic endpoints (autophagy, matrix remodeling, inflammatory signaling) in cell-based and in vivo disease models to establish mechanism-of-action and support patient selection for precision medicine approaches.
Innovation & enterprise leadership
- Designed innovative proof-of-mechanism studies using novel co-transduction strategies and mechanistic endpoint assays. Translated findings into clinical trial design recommendations and regulatory submissions.
- Led due diligence and asset evaluation for external programs. Provided scientific assessment informing critical strategic pivots and investment decisions.
- Directed strategic planning and timeline management from concept through IND-enabling development.
08 / 2007 — 09 / 2016
Boston University
Boston, MA
Senior Post-Doctoral Fellow // Translational Research Lab Director
Disease mechanism & translational biomarker discovery
- Established and led a translational research lab focused on mechanistic and therapeutic discovery in MDC1A congenital muscular dystrophy. Advanced the field through novel preclinical models and mechanistic insights translatable to clinical development.
- Identified and vetted novel therapeutic targets (IGF-1, matricellular proteins): assessed biological rationale and competitive differentiation. Established proof-of-mechanism in disease models, advancing innovative targets from hypothesis to translational strategy.
- Discovered and validated first synergistic therapy in CMD targeting both muscle regeneration and inflammation/fibrosis. A dual-mechanism approach later translated to clinical development. Featured in MDA Quest newsletter for disease impact.
- Developed and qualified translational biomarkers for non-invasive clinical monitoring: MRI (muscle imaging), EMG (neuromuscular function), and plethysmography (functional assessment). Established gold-standard endpoints for preclinical efficacy assessment and Phase I/II trial readiness.
- Identified matricellular proteins as key disease drivers through mechanistic studies; revealed novel therapeutic targets advancing understanding of fibrosis in CMD.
- Led cross-institutional biomarker harmonization: standardized protocols for translational endpoint measurement across academic and clinical networks.
09 / 2004 — 08 / 2007
Tufts University
Boston, MA
Post-Doctoral Fellow
- Conducted mechanistic drug discovery supporting early-stage compound evaluation in infectious disease. Cysteine protease inhibitors as candidate antimalarial agents (published J. Med. Chem.).
11 / 2003 — 09 / 2004
Harvard School of Medicine
Boston, MA
Post-Doctoral Fellow
- Structural and mechanistic studies supporting protein target validation. Cloning and characterization of Plasmodium falciparum cysteine protease falcipain-2B; erythroblast macrophage protein (Emp) subcellular dynamics.
03 / Capabilities
How I actually move a program forward.
Eight functional lenses I bring to every discovery program. Built across 15+ years at the bench and leading matrixed teams.
/ 01
Discovery–to–POC strategy
Inflammatory and immune-mediated disease biology. Target validation, lead optimization, Phase I-oriented translational strategy.
/ 02
Screening biology
Cell-based assay development, primary cell culture and phenotyping, high-content screening platforms, compound profiling.
/ 03
In vivo pharmacology
PK/PD, tissue distribution, and target engagement assessment. Efficacy studies in inflammatory, fibrotic, neuromuscular models.
/ 04
Translational biomarkers
Fit-for-purpose assays: multiplex ELISA, qPCR/ddPCR, NGS, flow, IHC/IF, high-content imaging. Cross-phase clinical harmonization.
/ 05
Regulatory & IND strategy
IND/CTA filings. Scientific justification for trial design, dose rationale, regulatory collaboration. GLP / GCLP / CLIA compliant.
/ 06
Discovery portfolio leadership
Disease-area portfolio goals, target/modality prioritization, data-driven go/no-go decisions in highly matrixed organizations.
/ 07
External innovation & BD
CRO/vendor management, academic collaborations, evaluating external platforms, due diligence for pipeline and technology opportunities.
/ 08
AI-augmented research
ML image analysis, imaging-data management systems, LLM-assisted literature triage, protein-design workflows via CROs.
04 / Expertise stack
The full technical surface.
A working inventory of platforms, models, modalities, and methods. Not a wish list. Each cell is hands-on or has been led end-to-end at Pfizer, Entrada, or in academic translational settings.
/ 01in vitro
HCS
High-content screening
Cell-based assay dev, primary cell culture & phenotyping, compound profiling.
/ 02assay
ELISA
Ligand-binding & protein quant
Multiplex ELISA, MSD, IHC/IF. Fit-for-purpose validation across biofluids and tissues.
/ 03na
qPCR
Nucleic acid assays
qPCR, ddPCR, NGS, gene expression, viral genome quantitation.
/ 04flow
FACS
Flow cytometry
Immune phenotyping, cell-state analysis, biomarker readouts.
/ 05in vivo
PK/PD
In vivo pharmacology
PK/PD, tissue distribution, target engagement, dose-response, efficacy.
/ 06model
Dyw
Disease models
Inflammatory & fibrotic models. Neuromuscular: MDC1A, DMD. Mechanism-of-action work.
/ 07imaging
MRI
Non-invasive imaging biomarkers
MRI (T2 mapping), EMG, plethysmography. Translational endpoints qualified to clinical.
/ 08tissue
Path
Histopathology
Cryosection protocols (published J. Vis. Exp.). Inflammation, fibrosis, matrix-remodeling readouts.
/ 09modality
SM
Small-molecule drug discovery
Hit → lead → PCC. Pharmacology cascade integration with DMPK and safety data.
/ 10modality
AAV
Gene & RNA therapies
AAV gene therapy biomarker strategy (Pfizer). Oligonucleotide programs (Entrada). CNS & muscle.
/ 11reg
IND
IND / CTA submissions
Authored biomarker strategy sections; integrated DMPK / safety into stage-gate decisions. FDA, EMA, ICH.
/ 12ops
CRO
CRO management
Vendor selection, SOW, milestone, budget, data-quality oversight, regulatory compliance.
Therapeutic areas
Disease biology I've published in, screened against, or led discovery programs for.
Biomarker strategy
Discovery, qualification, and clinical translation of fit-for-purpose biomarker platforms.
Tooling & platforms
Software stack underneath the science.
06 / Selected work
Publications, patents & presentations.
12 peer-reviewed papers, 2 patent families with international coverage, 30+ posters and talks. A subset are highlighted below.
Featured publications
2011
Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A.
Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Hum Mol Genet. 2011 Jun 15;20(12):2333–2343.
Established proof-of-mechanism for muscle-regeneration–based therapy in CMD. Foundation for downstream dual-mechanism work.
2013
Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1A.
Yamauchi J, Kumar A, Duarte L, Mehuron T, Girgenrath M. Hum Mol Genet. 2013 Nov 1;22(21):4306–4317.
First report of synergistic dual-mechanism therapy in CMD. Featured in MDA Quest. Established framework for mechanistic clinical trial design.
2015
Magnetic resonance imaging is sensitive to pathological amelioration in a model for laminin-deficient congenital muscular dystrophy (MDC1A).
Vohra R, Accorsi A, Kumar A, Walter G, Girgenrath M. PLoS One. 2015 Sep 17;10(9):e0138254.
Established MRI as sensitive translational biomarker for inflammation and fibrosis in rare neuromuscular disease.
2014
Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy.
Mehuron T, Kumar A, Duarte L, Yamauchi J, Accorsi A, Girgenrath M. Skelet Muscle. 2014 Jul 2;4:14.
Identified matricellular proteins as early disease drivers. Revealed novel therapeutic targets for fibrosis in CMD.
Full publication record
2017
Willmann R, Gordish-Dressman H, Meinen S, Rüegg MA, Yu Q, Nagaraju K, Kumar A, Girgenrath M, et al. Improving reproducibility of phenotypic assessments in the DyW mouse model of laminin-α2 related congenital muscular dystrophy.
J Neuromuscul Dis
4(2):115–126
4(2):115–126
2016
Accorsi A, Kumar A, Rhee Y, Miller A, Girgenrath M. IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy.
Hum Mol Genet
25(21):4624–4634
25(21):4624–4634
2015
Vohra R, Accorsi A, Kumar A, Walter G, Girgenrath M. Magnetic resonance imaging is sensitive to pathological amelioration in a model for laminin-deficient congenital muscular dystrophy (MDC1A).
PLoS One
10(9):e0138254
10(9):e0138254
2015
Kumar A, Accorsi A, Rhee Y, Girgenrath M. Do's and don'ts in the preparation of muscle cryosections for histological analysis.
J Vis Exp
(99):e52793
(99):e52793
2015
Accorsi A, Mehuron T, Kumar A, Rhee Y, Girgenrath M. Integrin dysregulation as a possible driver of matrix remodeling in laminin-deficient congenital muscular dystrophy (MDC1A).
J Neuromuscul Dis
2(1):51–61
2(1):51–61
2014
Mehuron T, Kumar A, Duarte L, Yamauchi J, Accorsi A, Girgenrath M. Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy.
Skelet Muscle
4:14
4:14
2013
Yamauchi J, Kumar A, Duarte L, Mehuron T, Girgenrath M. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1A.
Hum Mol Genet
22(21):4306–4317
22(21):4306–4317
2011
Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A.
Hum Mol Genet
20(12):2333–2343
20(12):2333–2343
2007
Soni S, Bala S, Kumar A, Hanspal M. Changing pattern of the subcellular distribution of erythroblast macrophage protein (Emp) during macrophage differentiation.
Blood Cells Mol Dis
38(1):25–31
38(1):25–31
2006
Micale N, Kozikowski AP, Ettari R, Grasso S, Zappalà M, Jeong JJ, Kumar A, Hanspal M, Chishti AH. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents.
J Med Chem
49(11):3064–3067
49(11):3064–3067
2006
Jeong JJ, Kumar A, Hanada T, Seo PS, Li X, Hanspal M, Chishti AH. Cloning and characterization of Plasmodium falciparum cysteine protease, falcipain-2B.
Blood Cells Mol Dis
36(3):429–435
36(3):429–435
2006
Bala S, Kumar A, Soni S, Sinha S, Hanspal M. Emp is a component of the nuclear matrix of mammalian cells and undergoes dynamic rearrangements during cell division.
Biochem Biophys Res Commun
342(4):1040–1048
342(4):1040–1048
Patents
[ pending · WIPO ]
Oligonucleotides for Treatment of Muscle Diseases
Translates platform chemistry into a candidate therapeutic for genetic muscle disease. Output of Entrada translational program.
[ granted · 5 jurisdictions ]
Method for Detecting Pathogenic Mycobacteria in Clinical Specimens
Diagnostic IP originating from infectious-disease postdoctoral and Ph.D. work on mycobacterial dormancy.
Posters & presentations
[ scientific meetings ]
30+
Featured venues
A 16-year record of posters and presentations across muscular-dystrophy and broader neuromuscular research, from early MDC1A disease-biology studies to preclinical DMD oligonucleotide programs at Entrada.
MDA International Meeting
World Muscle Society
Cure Duchenne
TREAT-NMD (Brussels)
New Directions in Skeletal Muscle
Frontiers in Myogenesis
Muscle Wasting Meeting (Ascona)
Brigham & Women's Hospital
Highlight: Cross-institutional MRI imaging work with the Walter / Vandenborne labs (Florida) used T2 relaxation mapping in dy2J/dy2J and dy3K/dy3K laminin-α2 models alongside mdx to differentiate distinct degeneration patterns. This work directly bridged preclinical models to pediatric clinical trials by validating T2 mapping as a surrogate endpoint for gene therapies and antisense oligonucleotides.
GenBank submissions
AJ249386
Kumar A, Rawat VPS, Das RH. Cloning, expression and characterization of globin-like genes of Mycobacterium in insect cells (sf9).
M. smegmatis
gi:5918200
gi:5918200
AY726608
Mishra G, Das RH, Kumar A. Molecular characterization of the protein kinase-1 gene of Spodoptera litura nucleopolyhedrosis virus.
Spodoptera litura
gi:52547775
gi:52547775
07 / Contact